Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · people with AMD
Omega 3 fatty acids probably leads to higher loss of 3 or more lines of VA at 24 months compared with placebo (moderate certainty).
2 findings from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF
Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).
1 finding from 1 review
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review
Intervention not reported
Change in long‐term disability more than 3 months after the intervention Measure:6MWT · People with multiple sclerosis
1 finding from 1 review
Intervention not reported
Change in long‐term impairments more than 3 months after the intervention Measures: FIS, FSS · People with multiple sclerosis
1 finding from 1 review
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression (increase in maximal keratometry of 1.5 dioptres or more) · people with keratoconus
It is very uncertain whether the intervention changes progression (increase in maximal keratometry of 1.5 dioptres or more) (very low certainty).
1 finding from 1 review
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review
ANC coverage: four or more visits · pregnant women
One intervention leads to higher ANC coverage: four or more visits compared with no intervention (high certainty).
1 finding from 1 review
ANC coverage: one or more visits · pregnant women
Combination of interventions probably leads to higher ANC coverage: one or more visits compared with no intervention (moderate certainty).
1 finding from 1 review